Efficacy of vitamin D3 supplementation in reducing incidence of pulmonary tuberculosis and mortality among HIV-infected Tanzanian adults initiating antiretroviral therapy: study protocol for a randomized controlled trial

Table 1 Vitamin D₃ content of trial supplements by batch at production and at end of shelf-life as assessed by high-performance liquid chromatography (HPLC)

	Batch #1 at production (December 2013)	Batch #1 at end of shelf-life (September 2015)	Batch #2 at production (November 2015)	Batch #2 at end of shelf-life
50,000 IU Vitamin D₃	50,949 IU (101.9%)	48,210 IU (96.4%)	52,325 IU (104.7%)	Currently in use
Matching Placebo for 50,000 IU	None detected	None detected	None detected	Currently in use
2000 IU Vitamin D₃	2076 IU (103.8%)	2103 IU (105%)	2162 IU (108.1%)	Currently in use
Matching Placebo for 2000 IU	None detected	None detected	None detected	Currently in use

ISSN: 1745-6215